Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jun 12, 2024 10:33am
179 Views
Post# 36084695

RE:RE:Multiple thoughts.

RE:RE:Multiple thoughts.Q30.
with all your brilliance, you must have a PhD.
you should apply for the CEO
or perhaps you are just another FUDster taking portions of statements out of context.
You are correct , the additional biomarker studies, were suggestions.
they were/ are also backed by the potential pharma partners.
They did an online video update, with various KOL, at the time.
Amungst all of them, leading to the biomarkers was considered a good utilization; of time.
The only reason the say " potential " , is because the FDA has not yet approved, as part if the phase 3 trial.
Closing the loop of my post.
The biomarkers have clearly been proven & identified.
they have asked FDA to allow them as part of phase 3 design.
once thst answer is received, they will have a complete set up of phase 3 design.
Not sure IF you have ever read a FDA trial/ study design?
lots avsible.
FYI, The page of exclusions. Meaning what a person can or can not have as precondition, is 2 pages long.
The requirements, agsin, multiple pages of checks & balances.
i was part of a phase 2b trial years ago. Nothing at all to do with cancer.
The pre- qualification interview was two hours & thst was after filling out many pages of medical history 
point?
When the FDA , outside agencies & medical advisors recommend something, good mangement will listen.
an improperly designed trial can fail. Just on the study itself.
de- risk? Involves addressing all forsesble issues ahead of time.
Thst takes time, 
Two ways to do everything the right way & twice.
They want Pela approved. Proper trial design.
the biomarkers, give a huge advantage . Being able to pre- screen the non- responders.


<< Previous
Bullboard Posts
Next >>